Key Details
Price
$0.85Annual ROE
201.12%Beta
0.34Events Calendar
Next earnings date:
Dec 13, 2024Recent quarterly earnings:
June 14, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jan 02, 2020Analyst ratings
Recent major analysts updates
03 Oct '24 HC Wainwright & Co.
Buy19 Sept '24 HC Wainwright & Co.
Buy11 Sept '24 HC Wainwright & Co.
Buy04 June '24 HC Wainwright & Co.
Buy24 May '24 HC Wainwright & Co.
BuyMarket Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
BriaCell Therapeutics doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing Concerns
BCTX
seekingalpha.com22 October 2024
BriaCell Therapeutics' lead candidate, Bria-IMT, shows promising trial results for metastatic breast cancer, potentially doubling overall survival and median progression-free survival. Despite a market cap below $30 million, BriaCell could tap into a $1-$5 billion market upon approval, with valuations between $1-$2 billion. Financing and shareholder dilution remain significant concerns, with recent offerings raising $18.5 million but also massively increasing the share count.
What Makes BRIACELL THERAP (BCTX) a New Strong Buy Stock
BCTX
zacks.com27 September 2024
BRIACELL THERAP (BCTX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday
BCTX
benzinga.com11 September 2024
On Wednesday, BriaCell Therapeutics BCTX stock traded higher with a session volume of 113.08 million, compared to the average volume of 366.19 thousand, according to data from Benzinga Pro.
FAQ
- What is the primary business of BriaCell Therapeutics?
- What is the ticker symbol for BriaCell Therapeutics?
- Does BriaCell Therapeutics pay dividends?
- What sector is BriaCell Therapeutics in?
- What industry is BriaCell Therapeutics in?
- What country is BriaCell Therapeutics based in?
- When did BriaCell Therapeutics go public?
- Is BriaCell Therapeutics in the S&P 500?
- Is BriaCell Therapeutics in the NASDAQ 100?
- Is BriaCell Therapeutics in the Dow Jones?
- When was BriaCell Therapeutics's last earnings report?
- When does BriaCell Therapeutics report earnings?
- Should I buy BriaCell Therapeutics stock now?
What is the primary business of BriaCell Therapeutics?
BriaCell Therapeutics is a biotechnology company focused on developing innovative immunotherapies for cancer treatment. Their lead product, Bria-IMT, aims to stimulate the immune system to target and destroy cancer cells, particularly in breast cancer patients. The company is dedicated to improving patient outcomes through advanced therapies.
What is the ticker symbol for BriaCell Therapeutics?
The ticker symbol for BriaCell Therapeutics is NASDAQ:BCTX
Does BriaCell Therapeutics pay dividends?
No, BriaCell Therapeutics does not pay dividends
What sector is BriaCell Therapeutics in?
BriaCell Therapeutics is in the Healthcare sector
What industry is BriaCell Therapeutics in?
BriaCell Therapeutics is in the Biotechnology industry
What country is BriaCell Therapeutics based in?
BriaCell Therapeutics is headquartered in Canada
When did BriaCell Therapeutics go public?
BriaCell Therapeutics's initial public offering (IPO) was on 14 March 2012
Is BriaCell Therapeutics in the S&P 500?
No, BriaCell Therapeutics is not included in the S&P 500 index
Is BriaCell Therapeutics in the NASDAQ 100?
No, BriaCell Therapeutics is not included in the NASDAQ 100 index
Is BriaCell Therapeutics in the Dow Jones?
No, BriaCell Therapeutics is not included in the Dow Jones index
When was BriaCell Therapeutics's last earnings report?
BriaCell Therapeutics's most recent earnings report was on 14 June 2024
When does BriaCell Therapeutics report earnings?
The next expected earnings date for BriaCell Therapeutics is 13 December 2024
Should I buy BriaCell Therapeutics stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions